BJU international

publication venue for

External validation of an artificial intelligence model for Gleason grading of prostate cancer on prostatectomy specimens. 2024
Impact of the extent of lymph node dissection on survival outcomes in clinically lymph node-positive bladder cancer. 2023
Continent diversion is losing its momentum: a nationwide trend analysis from Germany 2005-2021. 2023
Localised non-metastatic sarcomatoid renal cell carcinoma: a 31-year externally verified study.. 133. 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.. 132. 2023
Findings from an International Survey of Urology Trainee Experience with Prostate Biopsy. 2022
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.. 131. 2022
Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.. 131. 2022
Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?. 131. 2022
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.. 128. 2021
Pathological and oncological outcomes in patients with sarcomatoid differentiation undergoing cystectomy. 2021
A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.. 129. 2021
Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert^® Bladder Cancer Monitor) for surveillance in patients with non-muscle-invasive bladder cancer. 2021
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis.. 128. 2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.. 127. 2020
A risk calculator predicting recurrence in lymph node metastatic penile cancer.. 126. 2020
A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.. 126. 2020
Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.. 127. 2020
Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma.. 125. 2020
Extraperitoneal single-port robot-assisted radical prostatectomy: initial experience and description of technique.. 125. 2019
Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis.. 124. 2019
A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.. 124. 2019
Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes among selected centres in North America and Europe: an international multicentre collaboration. 2019
Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy.. 124. 2019
Step-by-step technique for single-port robot-assisted radical cystectomy and pelvic lymph nodes dissection using the da Vinci^® SP™ surgical system.. 124. 2019
Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer.. 123. 2019
Robot-assisted surgery for benign distal ureteral strictures: step-by-step technique using the SP^® surgical system.. 123. 2019
The duration of infertility affects semen parameters in primary infertile men: results of a single-centre, cross-sectional study.. 123. 2018
Achieving tumour control when suspecting sinus fat involvement during robot-assisted partial nephrectomy: step-by-step.. 123. 2018
Undiagnosed prediabetes is highly prevalent in primary infertile men - results from a cross-sectional study.. 123. 2018
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.. 123. 2018
Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer.. 122. 2018
Robot-assisted transvesical partial prostatectomy using a purpose-built single-port robotic system.. 122. 2018
First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy.. 121. 2017
Impact of bladder cancer on health-related quality of life.. 121. 2017
Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration.. 121. 2017
The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT_2-3 non-metastatic renal cell carcinoma treated with radical nephrectomy.. 121. 2017
Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.. 121. 2017
Risk of hospitalisation after primary treatment for prostate cancer.. 120. 2016
Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men.. 119. 2016
Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy.. 119. 2016
Robot-assisted partial cystectomy: perioperative outcomes and early oncological efficacy.. 119. 2016
Magnetic resonance microscopy may enable distinction between normal histomorphological features and prostate cancer in the resected prostate gland.. 119. 2016
Performance of robotic simulated skills tasks is positively associated with clinical robotic surgical performance.. 118. 2016
Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.. 119. 2016
The safety of robot-assisted cystectomy in patients with previous history of pelvic irradiation.. 118. 2016
Risk of prostate cancer-specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.. 118. 2016
A survey of patient expectations regarding sexual function following radical prostatectomy.. 118. 2016
Multiphoton microscopy for rapid histopathological evaluation of kidney tumours.. 118. 2015
The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.. 118. 2015
Variation in serum prostate-specific antigen levels in men with prostate cancer managed with active surveillance.. 118. 2015
Population-based assessment of cancer-specific mortality after local tumour ablation or observation for kidney cancer: a competing risks analysis.. 118. 2015
Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. 118. 2015
Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study.. 118. 2015
Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.. 117. 2015
Patterns of surveillance imaging after nephrectomy in the Medicare population.. 117. 2015
Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades.. 117. 2015
Prediction of cancer-specific survival after radical cystectomy in pT4a urothelial carcinoma of the bladder: development of a tool for clinical decision-making.. 117. 2015
Real-time in vivo periprostatic nerve tracking using multiphoton microscopy in a rat survival surgery model: a promising pre-clinical study for enhanced nerve-sparing surgery.. 116. 2015
Is continent cutaneous urinary diversion a suitable alternative to orthotopic bladder substitute and ileal conduit after cystectomy?. 116. 2015
Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.. 116. 2015
Preoperative predictive model of recovery of urinary continence after radical prostatectomy.. 116. 2015
Inhibition of urothelial P2X3 receptors prevents desensitization of purinergic detrusor contractions in the rat bladder.. 116. 2015
The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study.. 116. 2015
Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients.. 115. 2015
Extended pelvic lymph node dissection in patients with prostate cancer previously treated with surgery for lower urinary tract symptoms.. 116. 2015
The effect of hypogonadism and testosterone-enhancing therapy on alkaline phosphatase and bone mineral density.. 115. 2015
Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer.. 116. 2014
Enzalutamide in European and North American men participating in the AFFIRM trial.. 115. 2014
Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma.. 114. 2014
Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer.. 115. 2014
Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis.. 114. 2014
Subtyping of renal cortical neoplasms in fine needle aspiration biopsies using a decision tree based on genomic alterations detected by fluorescence in situ hybridization.. 114. 2014
Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.. 114. 2014
Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy.. 114. 2014
Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC).. 115. 2014
Erectile dysfunction in men treated for testicular cancer.. 113. 2014
Predictors of survival in patients with disease recurrence after radical nephroureterectomy.. 113. 2014
Preoperative serum albumin is associated with mortality and complications after radical cystectomy.. 113. 2014
Efficacy of robot-assisted radical cystectomy (RARC) in advanced bladder cancer: results from the International Radical Cystectomy Consortium (IRCC).. 114. 2014
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.. 113. 2014
Microsurgical denervation of rat spermatic cord: safety and efficacy data.. 113. 2014
Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis.. 114. 2014
Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder.. 113. 2014
Reflex fluorescence in situ hybridization assay for suspicious urinary cytology in patients with bladder cancer with negative surveillance cystoscopy.. 114. 2014
Population-based determinants of radical prostatectomy operative time.. 113. 2014
Bladder outlet obstruction (BOO) in men with castration-resistant prostate cancer.. 114. 2013
Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC).. 113. 2013
MRI-safe robot for targeted transrectal prostate biopsy: animal experiments.. 113. 2013
Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score.. 113. 2013
Prospective analysis of penile length changes after radical prostatectomy.. 113. 2013
Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.. 112. 2013
Trends and inequalities in the surgical management of ureteric calculi in the USA.. 113. 2013
Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis.. 113. 2013
Radical prostatectomy vs radiotherapy vs observation among older patients with clinically localized prostate cancer: a comparative effectiveness evaluation.. 113. 2013
Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project).. 112. 2013
Effect of statin use on outcomes of non-muscle-invasive bladder cancer.. 112. 2013
In-hospital mortality and failure-to-rescue rates after radical cystectomy.. 112. 2013
Cost-effectiveness analysis of tension-free vaginal tape vs burch colposuspension for female stress urinary incontinence in the USA.. 112. 2013
Sildenafil citrate improves erectile function after castration in a rat model.. 113. 2013
Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time.. 111. 2013
Sociodemographic disparities in the treatment of small renal masses.. 111. 2013
An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis.. 111. 2013
Phase II study of everolimus in metastatic urothelial cancer.. 112. 2013
Patterns of care and outcomes of radiotherapy for lymph node positivity after radical prostatectomy.. 111. 2013
Neutrophil gelatinase-associated lipocalin (NGAL) levels in response to unilateral renal ischaemia in a novel pilot two-kidney porcine model.. 112. 2013
Seminal vesicle involvement at salvage radical prostatectomy.. 111. 2013
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy.. 112. 2013
Can transrectal needle biopsy be optimised to detect nearly all prostate cancer with a volume of ≥0.5 mL? A three-dimensional analysis.. 112. 2013
Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data.. 113. 2013
Comparison of laparoendoscopic single site (LESS) and conventional laparoscopic donor nephrectomy at a single institution.. 112. 2013
Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study.. 112. 2013
Comparative assessment of three standardized robotic surgery training methods.. 112. 2013
Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes.. 112. 2013
Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.. 112. 2013
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007.. 112. 2013
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?. 112. 2013
Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC).. 111. 2013
Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer.. 111. 2013
A case-mix-adjusted comparison of early oncological outcomes of open and robotic prostatectomy performed by experienced high volume surgeons.. 111. 2013
Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.. 111. 2013
Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy.. 111. 2012
Perioperative outcomes of off-clamp vs complete hilar control laparoscopic partial nephrectomy.. 111. 2012
Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis.. 111. 2012
Uncertainty and perception of danger among patients undergoing treatment for prostate cancer.. 111. 2012
Cost-effective treatment of low-risk carcinoma not invading bladder muscle.. 111. 2012
Predictors of cancer-specific mortality after disease recurrence following radical cystectomy.. 111. 2012
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.. 111. 2012
Outpatient urological procedures in antibiotic-naive patients with bladder cancer with asymptomatic bacteriuria.. 110. 2012
Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy.. 111. 2012
Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy.. 111. 2012
Defining the impact of vascular risk factors on erectile function recovery after radical prostatectomy.. 111. 2012
Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvant therapies after radical cystectomy.. 110. 2012
Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.. 111. 2012
Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma.. 111. 2012
Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities.. 111. 2012
Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC).. 110. 2012
Modulation of bladder afferent signals in normal and spinal cord-injured rats by purinergic P2X3 and P2X2/3 receptors.. 110. 2012
Clomiphene citrate is safe and effective for long-term management of hypogonadism.. 110. 2012
Marital status: a gender-independent risk factor for poorer survival after radical cystectomy.. 110. 2012
Impact of age on clinicopathological outcomes and recurrence-free survival after the surgical management of nonseminomatous germ cell tumour.. 110. 2012
Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder.. 110. 2012
International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis.. 110. 2012
Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis.. 110. 2012
Venous thromboembolism after radical prostatectomy: the effect of surgical caseload.. 110. 2012
Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms.. 110. 2012
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.. 109. 2012
Comparative effectiveness of cryotherapy vs brachytherapy for localised prostate cancer.. 110. 2011
Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy.. 110. 2011
Perception of cancer and inconsistency in medical information are associated with decisional conflict: a pilot study of men with prostate cancer who undergo active surveillance.. 110. 2011
Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections.. 110. 2011
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer.. 110. 2011
Locally advanced prostate cancer: a population-based study of treatment patterns.. 109. 2011
Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.. 110. 2011
Screening urine analysis before bacille Calmette-Guérin instillation does not reduce the rate of infectious complications.. 109. 2011
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.. 109. 2011
Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort.. 110. 2011
Nodal counts during pelvic lymph node dissection for prostate cancer: an objective indicator of quality under the influence of very subjective factors.. 109. 2011
Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA.. 109. 2011
A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.. 109. 2011
Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.. 109. 2011
Open radical prostatectomy in the elderly: a case for concern?. 109. 2011
Anatomical grades of nerve sparing: a risk-stratified approach to neural-hammock sparing during robot-assisted radical prostatectomy (RARP).. 108. 2011
Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study.. 109. 2011
Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy.. 109. 2011
Symptom profile variability of interstitial cystitis/painful bladder syndrome by age.. 109. 2011
A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy.. 109. 2011
Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial.. 109. 2011
Measuring erectile function after radical prostatectomy: comparing a single question with the International Index of Erectile Function.. 109. 2011
Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis.. 109. 2011
Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.. 109. 2011
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.. 109. 2011
Defining predictors of response to intralesional verapamil injection therapy for Peyronie's disease.. 108. 2011
Evaluating the utility of a preoperative nomogram for predicting 90-day mortality following radical cystectomy for bladder cancer.. 109. 2011
Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.. 109. 2011
Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy.. 108. 2011
Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study.. 108. 2011
The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy.. 108. 2011
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.. 107 Suppl 2. 2011
Fifteen-year trend in the use of male reproductive surgery: analysis of the healthcare cost and utilization project data.. 107. 2011
Do pelvic dimensions and prostate location contribute to the risk of experiencing complications after radical prostatectomy?. 108. 2011
Multiphoton microscopy for structure identification in human prostate and periprostatic tissue: implications in prostate cancer surgery.. 108. 2011
Varicocele as a risk factor for androgen deficiency and effect of repair.. 108. 2011
Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration.. 108. 2011
Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma.. 108. 2011
Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort.. 107. 2011
Extending the indications and anatomical limits of pelvic lymph node dissection for prostate cancer: improved staging or increased morbidity?. 108. 2010
Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.. 108. 2010
Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer.. 108. 2010
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma.. 108. 2010
The impact of surgical experience on total hospital charges for minimally invasive prostatectomy: a population-based study.. 108. 2010
Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression.. 108. 2010
Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy.. 108. 2010
Trends in the care of radical prostatectomy in the United States from 2003 to 2006.. 108. 2010
Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort.. 108. 2010
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study.. 108. 2010
Anatomical retro-apical technique of synchronous (posterior and anterior) urethral transection: a novel approach for ameliorating apical margin positivity during robotic radical prostatectomy.. 106. 2010
Are histopathological features of prostate cancer lesions associated with identification of extracapsular extension on magnetic resonance imaging?. 106. 2010
Bladder cancer in cystoscopically normal-appearing mucosa: a case of mistaken identity?. 106. 2010
Location and number of positive surgical margins as prognostic factors of biochemical recurrence after salvage radiation therapy after radical prostatectomy.. 106. 2010
Partial nephrectomy for selected renal cortical tumours of ≥ 7 cm.. 106. 2010
Variability of treatment selection among surgeons for patients with cT1 urothelial carcinoma.. 106. 2010
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.. 107. 2010
Population-based determinants of radical prostatectomy surgical margin positivity.. 107. 2010
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder.. 106. 2010
Early oncological outcomes for bladder urothelial carcinoma patients treated with robotic-assisted radical cystectomy.. 107. 2010
Radical nephrectomy with vena caval thrombectomy: a contemporary experience.. 107. 2010
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.. 107. 2010
Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study.. 107. 2010
The depth of the prostatic apex is an independent predictor of positive apical margins at radical prostatectomy.. 106. 2010
Novel ZEB1 expression in bladder tumorigenesis.. 107. 2010
Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications.. 107. 2010
Reduced bladder tumour recurrence rate associated with narrow-band imaging surveillance cystoscopy.. 107. 2010
Urinary fistulae after partial nephrectomy.. 106. 2010
Visual cues as a surrogate for tactile feedback during robotic-assisted laparoscopic prostatectomy: posterolateral margin rates in 1340 consecutive patients.. 106. 2010
International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy.. 105. 2010
A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma.. 105. 2010
Lymph node dissection during robotic-assisted laparoscopic prostatectomy: comparison of lymph node yield and clinical outcomes when including common iliac nodes with standard template dissection.. 106. 2010
Extraprostatic extension of prostatic adenocarcinoma on needle core biopsy: report of 72 cases with clinical follow-up.. 106. 2009
Narrow-band imaging cystoscopy to evaluate bladder tumours--individual surgeon variability.. 106. 2009
Predicting individual outcomes after radical cystectomy: an external validation of current nomograms.. 106. 2009
The effect of gender on response to bacillus Calmette-Guérin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder.. 106. 2009
Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy.. 105. 2009
Narrow-band imaging cystoscopy to evaluate the response to bacille Calmette-Guérin therapy: preliminary results.. 105. 2009
Developments in the surgical management of sporadic synchronous bilateral renal tumours.. 105. 2009
Critical analysis of complications after robotic-assisted radical cystectomy with identification of preoperative and operative risk factors.. 105. 2009
A delay in radical nephroureterectomy can lead to upstaging.. 105. 2009
Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma.. 105. 2009
Biochemical recurrence rate in patients with positive surgical margins at radical prostatectomy with further negative resected tissue.. 104. 2009
p53 expression in patients with advanced urothelial cancer of the urinary bladder.. 105. 2009
Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease.. 105. 2009
Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial.. 105. 2009
Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies.. 105. 2009
Drug treatment of urological symptoms: estimating the magnitude of unmet need in a community-based sample.. 104. 2009
Incidental angiomyolipoma resected during renal surgery for an enhancing renal mass.. 104. 2009
External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma.. 104. 2009
High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.. 104. 2009
Impact of ethnicity on surgical margins at radical prostatectomy.. 104. 2009
Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma).. 104. 2009
Recovery of erectile function after radical prostatectomy is quantitatively related to the response to intraoperative cavernous nerve stimulation.. 104. 2009
Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.. 103. 2009
Outcomes after radical prostatectomy in men receiving previous pelvic radiation for non-prostate malignancies.. 104. 2009
p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.. 104. 2009
Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy.. 104. 2009
Metanephric adenoma of the kidney: clinical and radiological study of nine cases.. 103. 2009
A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study.. 103. 2008
Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer.. 103. 2008
P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells.. 102. 2008
Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density.. 103. 2008
Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients.. 103. 2008
Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.. 102. 2008
Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection.. 103. 2008
A comparison of white-light cystoscopy and narrow-band imaging cystoscopy to detect bladder tumour recurrences.. 102. 2008
Comparison of gelatine matrix-thrombin sealants used during laparoscopic partial nephrectomy.. 102. 2008
Contemporary imaging of patients with a renal mass: does size on computed tomography equal pathological size?. 103. 2008
Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy.. 102. 2008
Nitrofurantoin: the return of an old friend in the wake of growing resistance.. 102. 2008
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study.. 101. 2008
High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer.. 102. 2008
Features and outcomes of patients with grade IV renal injury.. 102. 2008
'Crushing the stone': a brief history of lithotripsy, the first minimally invasive surgery.. 102. 2008
Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.. 101. 2008
Accuracy of life tables in predicting overall survival in patients after radical prostatectomy.. 102. 2008
The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases.. 101. 2008
Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram.. 101. 2008
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.. 101. 2008
'Cutting for the stone': the ancient art of lithotomy.. 101. 2008
Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection.. 101. 2008
Modified technique for neurovascular bundle preservation during radical prostatectomy: association between technique and recovery of erectile function.. 101. 2008
Cancer control and the preservation of neurovascular tissue: how to meet competing goals during robotic radical prostatectomy.. 101. 2008
Adeno-associated viral vector transduction of green fluorescent protein in kidney: effect of unilateral ureteric obstruction.. 101. 2008
Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.. 101. 2008
Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer.. 100. 2007
Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading.. 100. 2007
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.. 101. 2007
Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner.. 101. 2007
Prognostic significance of altered p120 ctn expression in bladder cancer.. 101. 2007
Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy.. 101. 2007
Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.. 101. 2007
Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival.. 101. 2007
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome.. 100. 2007
Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin.. 100. 2007
Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.. 100. 2007
Prognostic significance of p27Kip1 expression in bladder cancer.. 100. 2007
Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.. 99. 2007
Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer.. 99. 2007
The proportion of cores with high-grade prostatic intraepithelial neoplasia on extended-pattern needle biopsy is significantly associated with prostate cancer on site-directed repeat biopsy.. 99. 2007
The role of the prostacyclin receptor antagonist RO3244019 in treating neurogenic detrusor overactivity after spinal cord injury in rats.. 99. 2007
The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis.. 99. 2007
Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.. 99. 2007
Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle-biopsy specimen.. 99. 2006
Impact of positive surgical margins in patients undergoing partial nephrectomy for renal cortical tumours.. 99. 2006
Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.. 99. 2006
African-American race is a predictor of prostate cancer detection: incorporation into a pre-biopsy nomogram.. 98. 2006
Trends in the operative management of renal tumors over a 14-year period.. 98. 2006
Radical prostatectomy in patients infected with human immunodeficiency virus.. 98. 2006
Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.. 98. 2006
The proximal neurovascular plate and the tri-zonal neural architecture around the prostate gland: importance in the athermal robotic technique of nerve-sparing prostatectomy.. 98. 2006
Comparison of outcomes in elective partial vs radical nephrectomy for clear cell renal cell carcinoma of 4-7 cm.. 97. 2006
Physiological fatigue of smooth muscle contractions in rat urinary bladder.. 97. 2006
Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival.. 97. 2006
A re-staging transurethral resection predicts early progression of superficial bladder cancer.. 97. 2006
Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.. 97. 2006
A population-based study of renal cell carcinoma and prostate cancer in the same patients.. 97. 2006
Mini-flank supra-11th rib incision for open partial or radical nephrectomy.. 97. 2006
Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?. 96. 2005
Laparoscopic vs open partial nephrectomy in consecutive patients: the Cornell experience.. 96. 2005
Urine cytology after flexible cystoscopy.. 96. 2005
Prospective analysis of outcomes after microsurgical intussusception vasoepididymostomy.. 96. 2005
Managing varicoceles in children: results with microsurgical varicocelectomy.. 95. 2005
Partial nephrectomy for patients with a solitary kidney: the Memorial Sloan-Kettering experience.. 94. 2004
Structural changes in the bladder walls of pregnant and hormone-treated rats: correlation with bladder dynamics.. 94. 2004
Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy.. 94. 2004
The impact of sildenafil citrate on sexual satisfaction profiles in men with a penile prosthesis in situ.. 93. 2004
Laparoscopically assisted ureterocystoplasty.. 91. 2003
The role of thoracotomy in managing postchemotherapy residual thoracic masses in patients with nonseminomatous germ cell tumours.. 91. 2003
Does cystoscopy correlate with the histology of recurrent papillary tumours of the bladder?. 88. 2001
Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system?. 87. 2001
The concealed laparoscopic orchidopexy.. 86. 2000
Intravasal azoospermia: a surgical dilemma.. 85. 2000
Chemotherapy, management of bladder tumours.. 85. 2000
Radiographic vs surgical size of renal tumours after partial nephrectomy.. 85. 2000
'Cello scrotum' hoax.. 103. 2009
Civiale, stones and statistics: the dawn of evidence-based medicine.. 104. 2009
Henry Wade (1876-1955): an early 20th century cancer researcher and pioneer urologist.. 98. 2006
Celestial bodies and urinary stones: Isaac Newton (1641-1727)--health and urological problems.. 95. 2005
Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme. 2006
Reply to Huseyin Besiroglu's Letter to the Editor regarding the article 'Do we need repeat transurethral resection after en bloc resection for pathological T1 bladder cancer?'. 2023
Continued gender imbalance on panels at urology meetings. 2023
Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?. 124. 2019
Potential new strategies for the treatment of renal medullary carcinoma.. 120. 2017
Active surveillance for prostate cancer: is it too active?. 118. 2016
Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy.. 113. 2014
Innovation vs experimentation - who decides?: Re: Sundaram V, Vemana G, Bhayani SB. Institutional Review Board approval and innovation in urology: current practice and safety issues. BJU Int 2014; 113: 343-7.. 113. 2014
The recurrence and progression risk after simultaneous endoscopic surgery of urothelial bladder tumour and benign prostatic hyperplasia: a systematic review and meta-analysis. 2020
A systematic review and meta-analysis of the impact of lymphovascular invasion in bladder cancer transurethral resection specimens. 2018
Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. 2017
Role of prostate artery embolization in the management of refractory haematuria of prostatic origin. 2016
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. 2014
Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. 2012
Testosterone in prostate cancer: the Bethesda consensus. 2011
Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). 2011
Cost-analysis comparison of robot-assisted laparoscopic radical cystectomy (RC) vs open RC. 2011
Current status of robotic partial nephrectomy (RPN). 2011
Review of current varicocelectomy techniques and their outcomes. 2011
Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. 2010
Partial nephrectomy for renal cancer (part II): the impact of renal ischaemia, patient preparation, surgical approaches, management of complications and utilization. 2010
Partial nephrectomy for renal cancer: Part I. 2010
Molecular events in germ cell tumours: linking chromosome-12 gain, acquisition of pluripotency and response to cisplatin. 2009
Retroperitoneal lymph node dissection after chemotherapy. 2009
Retroperitoneal lymph node dissection: reassessment of modified templates. 2009
A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer. 2009
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. 2008
Predicting survival after radical cystectomy for bladder cancer. 2008
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. 2005
Urinary function in female patients after traditional, organ-sparing and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analysis. 2023
Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis. 2023
Role of pelvic drain and timing of urethral catheter removal following RARP: a systematic review and meta-analysis. 2023
Oncological impact of cystoscopic findings in non-muscle-invasive bladder cancer: a meta-analysis. 2023
Iatrogenic ureteric injury during abdominal or pelvic surgery: a meta-analysis. 2022
Application of Artificial Intelligence to Overcome Clinical Information Overload in Urologic Cancer. 2021
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. 2021
Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. 2021
Association of erectile dysfunction and cardiovascular disease: an umbrella review of systematic reviews and meta-analyses. 2021
Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. 2020
Neoadjuvant systemic therapy for urological malignancies. 2010
Role of targeted therapy in the treatment of advanced prostate cancer. 2010
Management of good risk germ-cell tumours. 2009
Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. 2008
Signal-transduction inhibitors in renal cell carcinoma. 2007
Renal artery embolization: clinical indications and experience from over 100 cases. 2006
Satraplatin in the treatment of hormone-refractory prostate cancer. 2005
Chemotherapy and management of bladder tumours. 2000

VIVO Weill Cornell Medical College

BJU international Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)